PHASIQ provides scientists and clinicians with a cost- and time-efficient way of identifying multiple proteins in one culture sample, giving them a holistic view of the overall picture of a person's health. This allows scientists to quickly and more easily complete research to develop new drugs and enables clinicians to test for and diagnose multiple diseases at the same time. The company intends to use the funds to automate its manufacturing process to allow for scalable production of the finished first product.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/18/15 | undisclosed |
Zell Lurie Commercialization Fund | undisclosed |
